Point72 Asset Management L.P. Sells 1,245,687 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Point72 Asset Management L.P. cut its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 76.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 381,903 shares of the company's stock after selling 1,245,687 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.10% of GoodRx worth $1,776,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in GoodRx by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company's stock valued at $38,935,000 after purchasing an additional 460,753 shares during the period. Dimensional Fund Advisors LP raised its position in shares of GoodRx by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after acquiring an additional 369,553 shares during the period. Clearbridge Investments LLC acquired a new position in shares of GoodRx in the fourth quarter worth about $5,863,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of GoodRx by 38.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock worth $5,714,000 after acquiring an additional 342,781 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock worth $4,986,000 after acquiring an additional 89,032 shares during the period. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Trading Up 1.5%

GDRX traded up $0.06 during trading on Tuesday, hitting $3.80. 148,273 shares of the company's stock were exchanged, compared to its average volume of 1,381,838. The stock has a 50 day moving average price of $4.36 and a 200 day moving average price of $4.57. GoodRx Holdings, Inc. has a 1 year low of $3.68 and a 1 year high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.36 billion, a P/E ratio of -126.50, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The company had revenue of $202.97 million for the quarter, compared to analysts' expectations of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm's revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.08 earnings per share. As a group, analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GDRX. Truist Financial decreased their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. The Goldman Sachs Group reduced their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. UBS Group reduced their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company dropped their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $6.55.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.